Últimas noticias sobre ZimVie (NASDAQ:ZIMV) Bolsa

ZimVie

ZimVie Inc is focused on the dental and spine markets and their respective growth drivers such as implants, surgical tools, bone graft substitutes, spinal fusion implants, non-fusion alternatives, and digital care management solutions. Business is organized into two operating segments the spine products segment and the dental products segment.

ZimVie Inc

In the current session, the stock is trading at $161.40, after a 0.09% spike. Over the past month, Booz Allen Hamilton Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) stock increased by 6.29%, and in the past year, by 27.44%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1728418508_0.png" alt="Past Year Chart" />

<h3>How Does Booz Allen Hamilton P/E Compare to Other Companies?</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Booz Allen Hamilton has a lower P/E than the aggregate P/E of 46.25 of the Professional Services industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1728418508_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

News

Intraday Update

Markets

P/E Ratio Insights for Booz Allen Hamilton

VXRT

Vaxart Provided Notice To Sales Agents To Terminate Sales Agreement, Effective Oct 18; Will Not Incur Any Termination Penalties As Result Of Termination

Getting income from stock investments is why many invest in certain companies. It can provide a stable cash stream while offering the benefit of potential appreciation in stock price. However, companies must balance how much they pay their shareholders through dividends and how much they retain to reinvest back in their business.
If a company has valuable projects to pursue but lacks cash, its high dividends could hurt shareholders in the long run. One way to measure a company&#39;s ability to reinvest is to look at the dividend payout ratio (DPR). This ratio shows the percentage of the company&#39;s earnings it pays out as dividends.
If the dividend payout ratio is too high, the company might not have the cash it needs to invest in potentially high-return projects in the future. This could include making large capital expenditures (CAPEX) or strategically acquiring another firm.
The inability to do this could negatively affect the stock price over time or prevent it from rising as much as it otherwise could. Below, I&#39;ll review three U.S. stocks with dividend yields over 5% and dividend payout ratios that allow for solid reinvestment back into their business. For this analysis, I&#39;ll use these companies&#39; next twelve-month (NTM) dividend yield, which is an average of analyst projections for the company&#39;s dividend yield.
<h2>Ford Motor: Lots of Dividend Income and Lots Left Over</h2>
First up is Ford Motor (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/f#NYSE">F</a>). Ford&#39;s NTM dividend yield of 5.6% is relatively high, and its dividend payout ratio over the last twelve months is low. It sits at just 13.8%, meaning that the company is retaining over 86% of its earnings to reinvest back into the firm. Based on the company&#39;s net income over the last twelve months, it has been over $3.3 billion, and the company has to put it toward different uses.
This gives Ford the flexibility to invest in projects, initiate a share buyback program, or increase dividends. This is crucial, as the automotive industry is capital-intensive, requiring significant investments in plants, property, and equipment to stay competitive. With the global shift toward electric vehicles, maintaining financial flexibility will help Ford remain nimble, allowing the company to adapt to market changes and meet evolving customer preferences. This ability to invest strategically is key to Ford&#39;s long-term success in the rapidly changing automotive landscape.
<h2>AT&amp;T: 5% Dividend While Investing Big in Fiber Optics</h2>
AT&amp;T (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/t#NYSE">T</a>) is a telecom company that provides big-time income to its shareholders while not overextending its commitments. Its 5.1% NTM dividend yield offers a solid base of return. Its dividend payout ratio is 64%. It&#39;s a bit higher than I would like to see, but it&#39;s below 75%, where concerns about sustainability may arise. Again, its industry is key to why the company must retain earnings to compete effectively. AT&amp;T is investing heavily in fiber optics to connect more homes and businesses to the Internet.
Building fiber optic networks requires digging trenches on land or underwater or building above-ground cable systems. These cables physically connect buildings to centralized data centers, allowing for faster internet speeds. Thus, these investments require significant CAPEX from AT&amp;T. The company is doing just that, having spent $17.4 billion in CAPEX over the last twelve months. Fiber optics investments are vital to the firm&#39;s strategic plan to compete with large telecom firms.
<h2>Ares Capital&#39;s Dividend Strategy Balances Payouts and Growth Potential</h2>
Last on the list is Ares Capital (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arcc#NASDAQ">ARCC</a>). Ares is a business development company (BDC). BDCs invest in private companies using both debt and equity. Because of this, investing in Ares is an indirect way to gain some exposure to private debt and private equity, making Ares an interesting stock. On top of this, Ares also provides its shareholders a massive dividend yield.
Analysts project the number to sit at just under 9.3% over the next twelve months. In addition, its dividend payout ratio is 63%. Again, maybe a bit on the high side, but Ares is not in an industry that requires much in the way of capital expenditures.
However, retaining more of its net income does allow the company more &quot;dry powder&quot; to invest with. This means that if it sees an opportunity that could bring in particularly high returns but requires a large upfront investment, it could be more capable of executing the deal.
The article &quot;<a href="https://www.marketbeat.com/stock-ideas/maximize-your-returns-3-dividend-stocks-with-yields-over-5/">Maximize Your Returns: 3 Dividend Stocks With Yields Over 5%</a>&quot; first appeared on MarketBeat.

Earnings

Large Cap

Dividends

Offerings

Trading Ideas

ARCC

Maximize Your Returns: 3 Dividend Stocks With Yields Over 5%

DA Davidson analyst Peter Heckmann maintains Euronet Worldwide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EEFT#NASDAQ">EEFT</a>) with a Buy and maintains $136 price target.

Price Target

Analyst Ratings

EEFT

DA Davidson Maintains Buy on Euronet Worldwide, Maintains $136 Price Target

DA Davidson analyst Brent Thielman maintains Apogee Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APOG#NASDAQ">APOG</a>) with a Neutral and raises the price target from $65 to $75.

APOG

DA Davidson Maintains Neutral on Apogee Enterprises, Raises Price Target to $75

WIIM

CRDL

Cardiol Therapeutics shares are trading lower after the company announced a preliminary prospectus for a proposed public offering of common stock, size or amount not disclosed.

The new platform fundamentally changes how the company builds products and will provide expanded commerce capabilities like Pre-Auth and Bar Tabs to sellers of all sizes across verticals in the U.S.

Square Reports General Availability Of New Orders Platform

Management

SANA

Sana Biotechnology Announces Susan Wyrick Appointed Interim CFO Of Co

Crocs, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crox#NASDAQ">CROX</a>) stock seems in a good spot since the past year, with shares rising more than 60%, comfortably outperforming the broader Consumer Discretionary sector&#39;s return of 18.5% and the Zacks Textile - Apparel industry&#39;s growth of 4.8% in the same period. CROX&#39;s shares have also surpassed the S&amp;P 500 index&#39;s appreciation of 34.3% in a year.
Currently priced at $136.54, CROX stock is trading at 17.4% to its 52-week high of $165.32, reached on June 20, 2024. However, it is trading at an 84.5% premium to its 52-week low mark.
<h2>CROX&#39;s Strategies Aid the Rally</h2>
The company has been gaining from solid consumer demand across its Crocs and HEYDUDE brands, backed by effective pricing actions. Strength in clogs, sandals and personalization is acting as a tailwind. CROX has built various successful franchises, focused on expanding new usage occasions to boost new and repeat purchases. The sandal category further strengthened as consumers gave positive feedback to its innovation.
Management continues to view personalization as a mega consumer trend, with the opportunity of expanding the Jibbitz penetration in 2024 via higher penetration within digital and wholesale channels, continuous product freshness innovation and advancement in market capabilities. The company has been evolving its partnership model to boost engagement and consumer love.
<h2>CROX&#39;s Price Performance</h2>
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/c6/80801.jpg?v=1226149498" />
Image Source: Zacks Investment Research
Crocs aims at solidifying the business in North America and developing Wendy and Wally as iconic franchises. The company brought new HEYDUDE partnerships to the market, which include Corona, a four-piece collection with the iconic beverage band, featuring Wally, Wendy and Hudson Styles. Its Lee partnership, Denim and Dudes, highlighted the first HEYDUDE collaboration with international reach.
Crocs is on track with its long-term strategy and key initiatives to deliver sustainable growth. Its growth strategy is focused on three key initiatives. The first key initiative is igniting icons to enhance brand awareness and relevance. The second is investing strategically in Tier 1 markets to drive market share gains via talent, marketing, digital and retail. The third initiative is diversifying the product range to attract new consumers.
<h2>Earnings Estimate Revisions Favor Crocs</h2>
The aforesaid catalysts have prompted analysts to remain optimistic about CROX. The Zacks Consensus Estimate for 2024 and 2025 earnings has been northbound. In the past 30 days, the consensus estimate for earnings per share has been revised 0.3% to $12.88 for 2024 and 0.2% to $14.00 for 2025.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/c6/80815.jpg?v=687041234" />
Image Source: Zacks Investment Research
<h2>Unlocking CROX Stock&#39;s Valuation</h2>
Crocs stock is trading at an attractive valuation relative to the industry. Going by the price/earnings ratio, CROX&nbsp; is currently trading at 9.91 on a forward 12-month basis, lower than 12.68 of the industry. Also, the stock is trading lower than the S&amp;P 500 index&#39;s 21.69.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/c6/80814.jpg?v=1442318185" />
Image Source: Zacks Investment Research
<h2>Final Words on CROX</h2>
CROX stock is performing well on the bourses given its solid strategic efforts including strength in its brands. Solid upward revisions in earnings estimates and attractive valuation for the stock seem encouraging as well.
To wrap up, Crocs seems to be an attractive investment bet given all the aforementioned positives. The company currently sports a Zacks Rank #1 (Strong Buy).
<h2>Other Solid Picks</h2>
We have highlighted three other top-ranked stocks, namely, G-III Apparel Group (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/giii#NASDAQ">GIII</a>), Royal Caribbean (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rcl#NYSE">RCL</a>) and lululemon athletica (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lulu#NASDAQ">LULU</a>).
G-III Apparel is a manufacturer, designer and distributor of apparel and accessories under licensed brands, owned brands and private label brands. It sports a Zacks Rank of 1 at present.
GIII Apparel has a trailing four-quarter earnings surprise of 118.2%, on average. The Zacks Consensus Estimate for GIII Apparel&#39;s current financial-year sales indicates growth of 3.3% from the year-ago figure.
Royal Caribbean carries a Zacks Rank #2 (Buy) at present. RCL has a trailing four-quarter earnings surprise of 18.5%, on average.
The Zacks Consensus Estimate for RCL&#39;s 2024 sales and EPS indicates an increase of 18.2% and 70.9%, respectively, from the year-ago levels.
lululemon athletica is a yoga-inspired athletic apparel company. LULU carries a Zacks Rank of 2 at present.
The Zacks Consensus Estimate for lululemon athletica&#39;s current financial-year sales and EPS indicates growth of 9.2% and 9.8%, respectively, from the year-ago corresponding figures. LULU has a trailing four-quarter earnings surprise of 7.9%, on average.
<a href="https://www.zacks.com/stock/news/2347760/crocs-gains-on-brand-strength-other-efforts-apt-to-stay-invested?cid=CS-BENZ-FT-analyst_blog|rank_focused-2347760">To read this article on Zacks.com click here.</a>

Mid Cap

Small Cap

CROX

GIII

LULU

Crocs Gains on Brand Strength & Other Efforts: Apt to Stay Invested?

Shipping in pre-production quantities, Scorpio Smart Fabric Switches deliver maximum system utilization and uptime for scale-out PCIe 6 connectivity and scale-up GPU clustering in AI servers
Astera Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>), a global leader in semiconductor-based connectivity solutions for AI and cloud infrastructure, today announced a new portfolio of fabric switches, including the industry's first PCIe&#xAE; 6 switch, built from the ground up for demanding AI workloads in accelerated computing platforms deployed at cloud-scale. The Scorpio Smart Fabric Switch portfolio is optimized for AI dataflows to deliver maximum predictable performance per watt, high reliability, easy cloud-scale deployment, reduced time-to-market, and lower total cost of ownership.

ALAB

Astera Labs Introduces New Portfolio Of Fabric Switches Purpose-Built For AI Infrastructure At Cloud-Scale

DA Davidson analyst Michael Baker maintains Superior Gr of Cos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGC#NASDAQ">SGC</a>) with a Buy and maintains $24 price target.

DA Davidson Maintains Buy on Superior Gr of Cos, Maintains $24 Price Target

ImmuCell Corporation (Nasdaq:&nbsp;ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today&nbsp;announced preliminary, unaudited sales results for the third quarter of 2024, which ended September 30, 2024.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="6">Preliminary, Unaudited Total Sales Results: &nbsp;</td>
</tr>
<tr>
<td>2024</td>
<td>2023</td>
<td colspan="2">$ Increase</td>
<td colspan="1">% Increase</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>During the Three-Month Periods Ended September 30,</td>
<td>$6.0 million</td>
<td>$5.4 million</td>
<td colspan="2">$615,000</td>
<td>11%</td>
</tr>
<tr>
<td>During the Nine-Month Periods Ended September 30,</td>
<td>$18.7 million</td>
<td>$12.4 million</td>
<td colspan="2">$6.4 million</td>
<td>51%</td>
</tr>
<tr>
<td>During the Twelve-Month Periods Ended September 30,</td>
<td>$23.8 million</td>
<td>$16.3 million</td>
<td colspan="2">$7.6 million</td>
<td>46%</td>
</tr>
</tbody>
</table>
</figure>
 During the three-, nine- and twelve-month periods ended September 30, 2024, annualized production output was approximately 73%, 81% and 77%, respectively, of the Company's estimated full capacity of approximately $30 million per year.
As of September 30, 2024, the backlog of orders aggregated approximately $7.3 million. The Company believes that the current backlog reflects strong demand as distributors work to replenish their buffer stocks and as end-users place orders in advance of the first quarter calving season.
Since the first quarter of 2020, the Company has been providing a preliminary look at its unaudited top line results soon after the close of the quarter. The Company expects to continue providing this prompt, preliminary report on product sales until further notice going forward.

Guidance

ICCC

ImmuCell Announces Preliminary Q3 Revenue Of $6M Up From $5.4M YoY

Saratoga Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAR#NYSE">SAR</a>) reported quarterly earnings of $1.33 per share which beat the analyst consensus estimate of $0.94 by 41.49 percent. The company reported quarterly sales of $43.003 million which beat the analyst consensus estimate of $37.124 million by 15.84 percent. This is a 21.09 percent increase over sales of $35.514 million the same period last year.

Earnings Beats

Saratoga Investment Q2 2025 Adj. EPS $1.33 Beats $0.94 Estimate, Sales $43.003M Beat $37.124M Estimate

MYGN

Myriad Genetics Reveals Series Of Ongoing Research Collaborations To Study Use Of Molecular Residual Disease Testing In Breast Cancer Using Precise MRD Test

—Data Presented at the CHEST 2024 Annual Meeting—
BRIDGEWATER, N.J., Oct. 8, 2024 /PRNewswire/ -- Insmed Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today presented positive late-breaking subgroup data from the Phase 3 ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis. Posters with the details from these subgroup analyses can be found <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4272617-1&amp;h=1623866854&amp;u=https%3A%2F%2Finvestor.insmed.com%2Fevents%3Fitem%3D127&amp;a=HERE">HERE</a>. These data were presented at the CHEST 2024 Annual Meeting, held October 6-9 in Boston, along with several other presentations from across Insmed's respiratory portfolio.

Biotech

General

INSM

Insmed Inc Presents New Subgroup Analyses From Landmark Phase 3 ASPEN Study Of Brensocatib In Patients With Bronchiectasis Demonstrate Consistency With Overall Trial Population Results At The CHEST 2024 Annual Meeting

Delek Logistics Partners, LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKL#NYSE">DKL</a>) ("Delek Logistics") announced today that it has commenced an underwritten public offering of $150,000,000 of common units representing limited partner interests in Delek Logistics pursuant to an effective shelf registration statement previously filed with the Securities and Exchange Commission (the "SEC"). A preliminary prospectus supplement relating to the offering will also be filed with the SEC. Delek Logistics intends to grant the underwriters a 30-day option to purchase up to an additional $22,500,000 of common units. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Delek Logistics intends to use the net proceeds from the offering (including any net proceeds from the underwriters' exercise of their option to purchase additional common units) to redeem its outstanding convertible preferred units and to repay outstanding borrowings under its revolving credit agreement.
Avigal Soreq, our President and Chief Executive Officer, and certain other of our executives (collectively, the "Executives"), have indicated an interest in purchasing up to $300,000 of the common units offered in the offering at the price offered to the public. Because this indication is not a binding agreement or commitment to purchase, the Executives may elect not to purchase any units in the offering, or the underwriters may elect not to sell any units in the offering to the Executives.

Delek Logistics Partners, LP Announces $150M Proposed Public Offering Of Common Units

Cardiol Therapeutics Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/CRDL#NASDAQ">CRDL</a>) (TSX:<a href="https://www.benzinga.com/stock/CRDL#TSX">CRDL</a>) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce the Company has filed a preliminary prospectus supplement (the "Supplement") to its short form base shelf prospectus dated July 12, 2024 (the "Base Prospectus") in connection with a proposed public offering (the "Offering") of Class A common shares (the "Common Shares"). The Supplement was also filed with the U.S. Securities Exchange and Commission (the "SEC"), as part of a registration statement on Form-10, as amended, which was declared effective by the SEC on July 16, 2024, in accordance with the Multijurisdictional Disclosure System established between Canada and the United States.
The Company intends to use the net proceeds from the Offering to support the clinical development of CardiolRx for the treatment of recurrent pericarditis, and for general and administrative expenses, working capital and other expenses.
Canaccord Genuity is acting as the sole bookrunner in connection with the Offering.

Cardiol Therapeutics Files Preliminary Prospectus Supplement For Proposed Public Offering Of Common Shares; No Size Or Amount Disclosed

With 30-Day Option For Underwriters To Purchase Up To An Additional $60M

CRNX

Crinetics Pharmaceuticals Announces Proposed $400M Public Offering Of Common Stock; Proceeds To Fund R&D, Pre-Commercialization Activities, And Potential Acquisitions

S&P Says Estimate Strike Costs Boeing More Than $1B Per Month, After Considering Cost-Saving Measures It Implemented In Response

Throughout the last three months, 7 analysts have evaluated PROCEPT BioRobotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCT#NASDAQ">PRCT</a>), offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $83.57, a high estimate of $99.00, and a low estimate of $69.00. This upward trend is evident, with the current average reflecting a 12.07% increase from the previous average price target of $74.57.
<img src="https://www.benzinga.com/files/images/story/2024/1728417703_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive PROCEPT BioRobotics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Joshua Jennings</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$99.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$95.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Craig Bijou</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$94.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Nathan Treybeck</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$69.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$74.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$79.00</td>
<td>$72.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to PROCEPT BioRobotics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of PROCEPT BioRobotics compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of PROCEPT BioRobotics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of PROCEPT BioRobotics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/PRCT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on PROCEPT BioRobotics analyst ratings.</a>
<h2>Get to Know PROCEPT BioRobotics Better</h2>
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System,, image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. The company's assets are based in the United States. Its revenue is generated from sales of the AquaBeam Robotic System and the accompanying single-use disposable handpieces.
<h3>Financial Milestones: PROCEPT BioRobotics's Journey</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining PROCEPT BioRobotics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 61.17% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -48.03%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): PROCEPT BioRobotics's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -9.94%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): PROCEPT BioRobotics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -6.77%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.32, PROCEPT BioRobotics adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PRCT

What Analysts Are Saying About PROCEPT BioRobotics Stock

Dental implant maker ZimVie jumps after report it's evaluating sale

Analyst David Saxon of Needham reiterated a Buy rating on ZimVie Inc (ZIMV – Research Report), retaining the price target of $20.00. David Saxon ha...

Buy Rating Justified for ZimVie Inc Amid Potential Sale and Value Unlocking Opportunities

ZimVie may be worth $25-$29 a share in takeover - analyst

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth diving into this morning and we have all of the hottest news worth checking out on Thursday!



Moving stocks this morning are an acquisition deal, a clinical trial launch, earnings reports and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Chuy&rsquo;s (NASDAQ:<a href="https://investorplace.com/stock-quotes/chuy-stock-quote/">CHUY</a>) stock is rocketing more than 46% on a <a href="https://www.nasdaq.com/press-release/darden-restaurants-acquire-chuys-holdings-inc-approximately-605-million-transaction">$605 million acquisition deal</a>.</li>



<li>Onconetix (NASDAQ:<a href="https://investorplace.com/stock-quotes/onco-stock-quote/">ONCO</a>) shares are soaring over 43% alongside heavy pre-market trading.</li>



<li>Apollomics (NASDAQ:<a href="https://investorplace.com/stock-quotes/aplm-stock-quote/">APLM</a>) stock is surging more than 25% with strong early morning trading.</li>



<li>Bionomics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bnox-stock-quote/">BNOX</a>) shares are rising over 23% as it <a href="https://www.nasdaq.com/press-release/bionomics-initiates-affirm-1-phase-3-clinical-trial-bnc210-social-anxiety-disorder">kicks off a Phase 3 clinical trial</a>.</li>



<li>Big Tree Cloud (NASDAQ:<a href="https://investorplace.com/stock-quotes/dsy-stock-quote/">DSY</a>) stock is increasing more than 18% with strong pre-market trading.</li>



<li>ZimVie (NASDAQ:<a href="https://investorplace.com/stock-quotes/zimv-stock-quote/">ZIMV</a>) shares are heading over 13% higher without any clear news on Thursday morning.</li>



<li>SAI.TECH Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/sai-stock-quote/">SAI</a>) stock is gaining more than 12% on a <a href="https://www.globenewswire.com/news-release/2024/07/18/2914992/0/en/SAI-TECH-Global-Corporation-Announces-Share-Repurchase-Program.html">share repurchase program</a>.</li>



<li>MultiMetaVerse (NASDAQ:<a href="https://investorplace.com/stock-quotes/mmv-stock-quote/">MMV</a>) shares are climbing over 11% as it continues a recent rally.</li>



<li>Psyence Biomedical (NASDAQ:<a href="https://investorplace.com/stock-quotes/pbm-stock-quote/">PBM</a>) stock is jumping more than 10% despite a lack of news today.</li>



<li>XWELL (NASDAQ:<a href="https://investorplace.com/stock-quotes/xwel-stock-quote/">XWEL</a>) shares are up over 10% this morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Leslies (NASDAQ:<a href="https://investorplace.com/stock-quotes/lesl-stock-quote/">LESL</a>) stock is diving more than 21% on <a href="https://www.nasdaq.com/press-release/leslies-inc-announces-preliminary-third-quarter-fiscal-2024-financial-results-and">preliminary earnings and guidance</a>.</li>



<li>Aptevo Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/apvo-stock-quote/">APVO</a>) shares are rumbling over 13% after a massive rally yesterday.</li>



<li>Domino&rsquo;s Pizza (NYSE:<a href="https://investorplace.com/stock-quotes/dpz-stock-quote/">DPZ</a>) stock is sliding more than 13% with the release of its <a href="https://ir.dominos.com/static-files/68ecdbfc-bd1c-486a-a574-d6f54b7e5132">Q2 earnings report</a>.</li>



<li>CBL International (NASDAQ:<a href="https://investorplace.com/stock-quotes/banl-stock-quote/">BANL</a>) shares are taking an over 12% beating on Thursday morning as it retreats from a rally yesterday.</li>



<li>WiMi Hologram Cloud (NASDAQ:<a href="https://investorplace.com/stock-quotes/wimi-stock-quote/">WIMI</a>) stock is dropping close to 12% after an unexpected rally yesterday.</li>



<li>Beyond Meat (NASDAQ:<a href="https://investorplace.com/stock-quotes/bynd-stock-quote/">BYND</a>) shares are falling more than 11% on <a href="https://www.wsj.com/articles/beyond-meat-engages-bondholders-for-restructuring-talks-7de6b8ae">restructuring talks with bondholders</a>.</li>



<li>American Rebel (NASDAQ:<a href="https://investorplace.com/stock-quotes/areb-stock-quote/">AREB</a>) stock is decreasing over 11% this morning after rallying on Wednesday.</li>



<li>Aditxt (NASDAQ:<a href="https://investorplace.com/stock-quotes/adtx-stock-quote/">ADTX</a>) shares are slipping more than 10% <a href="https://investorplace.com/2024/07/why-is-aditxt-adtx-stock-up-72-today/">following a rally yesterday</a>.</li>



<li>Stardust Power (NASDAQ:<a href="https://investorplace.com/stock-quotes/sdst-stock-quote/">SDST</a>) stock is dipping over 10% <a href="https://investorplace.com/2024/07/stardust-power-sdst-stock-pops-140-days-after-debut-what-to-know/">after a surprise rally yesterday</a>.</li>



<li>GRI Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/gri-stock-quote/">GRI</a>) shares close out our pre-market stock movers down more than 9%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-july-18th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

ZimVie jumps after report on buyout talks with South Korea's Osstem

ZimVie launches GenTek Restorative Components in U.S.

ZimVie Non-GAAP EPS of $0.13 misses by $0.04, revenue of $116.8M beats by $1.6M

An announcement from ZimVie Inc (ZIMV) is now available. On August 1, 2024, the Company released a presentation offering supplemental financial inf...

ZimVie Inc Offers Updated Financial Guidance for 2024

Analyst David Saxon from Needham reiterated a Buy rating on ZimVie Inc (ZIMV – Research Report) and increased the price target to $23.00 from $20.0...

Buy Rating Affirmed for ZimVie Inc. Amid Market Challenges and Positive Growth Indicators

ZimVie Inc. (ZIMV) Q2 2024 Earnings Call Transcript

ADTX

APLM

APVO

AREB

BANL

BNOX

BYND

CHUY

HSIC

LESL

NVST

ONCO

SAUHF

SDST

WIMI

XRAY

XWEL

ZIMV

Press Releases

ZimVie to Participate in the 23rd Annual Needham Virtual Healthcare Conference

ZimVie Announces Closing of Sale of Spine Business

H.I.G. Capital Acquires the Spine Business of ZimVie Rebranded as Highridge Medical

ZimVie to Report First Quarter Financial Results on May 8, 2024

Health Care

ZimVie Reports First Quarter 2024 Financial Results

ZimVie to Participate in Upcoming Investor Conferences

ZimVie to Report Second Quarter Financial Results on August 1, 2024

ZimVie Announces FDA Clearance and U.S. Launch of GenTek® Restorative Components

Comments

ZimVie

Noticias

Últimas noticias sobre ZimVie (NASDAQ:ZIMV) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL